• Sunshine Biopharma shareholders authorized changes tied to Series C Warrants issued in a May 19, 2026 public offering.
• Authorization covers issuing more than 20% of outstanding common stock at a deemed discount to the Nasdaq Minimum Price.
• It also permits exercise-price or share-count adjustments for Series C Warrants tied to share combination events, including voluntary reductions.
• The offering sold 11,160,000 Common Units at $0.5, 840,000 Pre-Funded Units at $0.5, raising about $6 million gross.
• Each unit carried two Series C Warrants; the warrants start at a $0.5 exercise price, five-year term, with a $0.25 floor in share combination events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-004389), on May 29, 2026, and is solely responsible for the information contained therein.